Thursday 6-12-2014 Ariad Pharmaceuticals (ARIA) $ARIA opened at 6.65 hitting the high price of 6.75 and a day low of 6.35 with a total volume of 18,635,812. ARIA had a previous close of 7.02 and has been seeing an average volume of 8,373,436.
Overall Average: 80% Sell
Recent stock forum discussions about ARIA http://investorshangout.com/search?q=ARIA&...mp;yt0=Go!
Why Organovo Holdings, lululemon athletica, and Ariad Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - 1 hr 28 mins ago
Bad news in the Middle East is rarely good news for the stock market, and the rising tensions in Iraq were one of the primary factors pulling down stocks on Thursday. While it's too early to tell whether the long-term impact of the Iraqi situation... (full story)
Nasdaq stocks posting largest percentage decreases
AP - Thu Jun 12, 5:29PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: (full story)
Most active Nasdaq-traded stocks
AP - Thu Jun 12, 12:19PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.: (full story)
Will This Price Target Decrease Hurt Ariad Pharmaceuticals (ARIA) Stock Today?
at The Street - Thu Jun 12, 8:23AM CDT
UBS decreased its price target on Ariad Pharmaceuticals (ARIA) to $7 and set a "neutral" rating. The firm noted limited near-term drivers of upside risk. (full story)
Alcobra Ltd. (ADHD) Jumps: Stock Rises 8.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 8:18AM CDT
Alcobra Ltd. (ADHD) was a big mover last session, as the company saw its shares rise by roughly 9% on the day. (full story)
ARIAD Announces Pricing of $200 Million Offering of 3.625% Convertible Senior Notes Due 2019
Business Wire - Thu Jun 12, 8:15AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the pricing of $200 million aggregate principal amount of its 3.625% convertible senior notes due 2019 (the "Notes"
in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Act" . ARIAD also granted the initial purchasers of the Notes an option, exercisable for 30 days, to purchase up to an additional $30 million aggregate principal amount of the Notes on the same terms and conditions. As a result of the convertible note hedge and warrant transactions described below, the effective conversion price for the Notes is expected to be $12.00 per share, which represents a 71% premium over the closing price of ARIAD's common stock of $7.02 per share on June 11, 2014. (full story)
Auxilium Pharmaceuticals (AUXL) in Focus: Stock Tumbles 7.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 7:44AM CDT
Shares of Auxilium Pharmaceuticals fell nearly 8% last session and the stock is now down about 1% in the past one-month time frame, suggests that it requires a close watch of this firm in the near future. (full story)
ARIAD to issue USD175m convertible senior notes in private placement
M2 - Thu Jun 12, 5:10AM CDT
Oncology company ARIAD Pharmaceuticals (NasdaqGS:ARIA) said on Wednesday that it plans to offer USD175m aggregate principal amount of convertible senior notes due 2019 in a private placement. (full story)
Why Ariad Pharmaceuticals (ARIA) Stock Is Down in After-Hours Trading Today
at The Street - Wed Jun 11, 3:54PM CDT
Ariad Pharmaceuticals (ARIA) fell in after-hours trading Wednesday after the oncology company announced a proposed $175 million aggregate principal amount of convertible senior notes due 2019 in a private placement. (full story)
ARIAD Announces Proposed $175 Million Offering of Convertible Senior Notes Due 2019
Business Wire - Wed Jun 11, 3:01PM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its intention to offer, subject to market and other conditions, $175 million aggregate principal amount of convertible senior notes due 2019 (the "Notes" in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the "Act" . ARIAD also intends to grant the initial purchasers of the Notes an option, exercisable for 30 days, to purchase up to an additional $50 million aggregate principal amount of the Notes on the same terms and conditions. (full story)
Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 11, 11:16AM CDT
The week so far has been highly eventful (full story)
KaloBios (KBIO) Worth Watching: Stock Jumps 12.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 8:25AM CDT
KaloBios (KBIO) was a big mover last session, as the company saw its shares rise nearly 13% on the day. (full story)
Strength Seen in Receptos, Inc. (RCPT) as Stock Shoots up 36.78% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 7:44AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as the company saw its shares surge a whopping 37% on the day. (full story)
ARIAD Announces Webcast of Its Annual Shareholders Meeting
Business Wire - Wed Jun 11, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Annual Meeting of Stockholders will be webcast live on June 25, 2014 and can be accessed by visiting the investor relations section of the Company's website at: http://www.ariad.com/investor. (full story)
Ariad Pharmaceuticals Rises 3.02% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jun 10, 5:12PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.62 to a high of $6.88. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $6.86 on volume of 8.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 85.8% (ARIA)
Comtex SmarTrend(R) - Tue Jun 10, 10:58AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on November 22nd, 2013 at $3.67. In approximately 7 months, Ariad Pharmaceuticals has returned 85.83% as of today's recent price of $6.82. (full story)
Why Investors Are Wrong about Ariad
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jun 09, 2:51PM CDT
Ariad Pharmaceuticals has had a rough year, with the stock down over 60% on a variety of bad news for its primary drug Iclusig. More specifically, past issues with blood clots resulted in the drug being pulled from the market and then returned with... (full story)
Hyperion (HPTX) in Focus: Stock Tumbles 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 09, 7:55AM CDT
Shares of Hyperion fell about 6% on Friday while the stock is now up nearly 9% in the past one-month time frame, suggests that it requires a close watch of this firm in the near future. (full story)
Aerie Pharmaceuticals, Inc. (AERI) in Focus: Stock Rises 5.71% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 09, 7:44AM CDT
Aerie Pharmaceuticals, Inc. (AERI) was a big mover last session, as the company saw its shares rise nearly 6% on the day. (full story)
Insider Trading Alert - ENTA, REX And ARIA Traded By Insiders
at The Street - Thu Jun 05, 9:12AM CDT
Stocks with insider trader activity include ENTA, REX and ARIA (full story)
Overall Average: 80% Sell
Recent stock forum discussions about ARIA http://investorshangout.com/search?q=ARIA&...mp;yt0=Go!
Why Organovo Holdings, lululemon athletica, and Ariad Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - 1 hr 28 mins ago
Bad news in the Middle East is rarely good news for the stock market, and the rising tensions in Iraq were one of the primary factors pulling down stocks on Thursday. While it's too early to tell whether the long-term impact of the Iraqi situation... (full story)
Nasdaq stocks posting largest percentage decreases
AP - Thu Jun 12, 5:29PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: (full story)
Most active Nasdaq-traded stocks
AP - Thu Jun 12, 12:19PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.: (full story)
Will This Price Target Decrease Hurt Ariad Pharmaceuticals (ARIA) Stock Today?
at The Street - Thu Jun 12, 8:23AM CDT
UBS decreased its price target on Ariad Pharmaceuticals (ARIA) to $7 and set a "neutral" rating. The firm noted limited near-term drivers of upside risk. (full story)
Alcobra Ltd. (ADHD) Jumps: Stock Rises 8.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 8:18AM CDT
Alcobra Ltd. (ADHD) was a big mover last session, as the company saw its shares rise by roughly 9% on the day. (full story)
ARIAD Announces Pricing of $200 Million Offering of 3.625% Convertible Senior Notes Due 2019
Business Wire - Thu Jun 12, 8:15AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the pricing of $200 million aggregate principal amount of its 3.625% convertible senior notes due 2019 (the "Notes"
in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Act" . ARIAD also granted the initial purchasers of the Notes an option, exercisable for 30 days, to purchase up to an additional $30 million aggregate principal amount of the Notes on the same terms and conditions. As a result of the convertible note hedge and warrant transactions described below, the effective conversion price for the Notes is expected to be $12.00 per share, which represents a 71% premium over the closing price of ARIAD's common stock of $7.02 per share on June 11, 2014. (full story) Auxilium Pharmaceuticals (AUXL) in Focus: Stock Tumbles 7.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 7:44AM CDT
Shares of Auxilium Pharmaceuticals fell nearly 8% last session and the stock is now down about 1% in the past one-month time frame, suggests that it requires a close watch of this firm in the near future. (full story)
ARIAD to issue USD175m convertible senior notes in private placement
M2 - Thu Jun 12, 5:10AM CDT
Oncology company ARIAD Pharmaceuticals (NasdaqGS:ARIA) said on Wednesday that it plans to offer USD175m aggregate principal amount of convertible senior notes due 2019 in a private placement. (full story)
Why Ariad Pharmaceuticals (ARIA) Stock Is Down in After-Hours Trading Today
at The Street - Wed Jun 11, 3:54PM CDT
Ariad Pharmaceuticals (ARIA) fell in after-hours trading Wednesday after the oncology company announced a proposed $175 million aggregate principal amount of convertible senior notes due 2019 in a private placement. (full story)
ARIAD Announces Proposed $175 Million Offering of Convertible Senior Notes Due 2019
Business Wire - Wed Jun 11, 3:01PM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its intention to offer, subject to market and other conditions, $175 million aggregate principal amount of convertible senior notes due 2019 (the "Notes"
in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the "Act" . ARIAD also intends to grant the initial purchasers of the Notes an option, exercisable for 30 days, to purchase up to an additional $50 million aggregate principal amount of the Notes on the same terms and conditions. (full story) Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 11, 11:16AM CDT
The week so far has been highly eventful (full story)
KaloBios (KBIO) Worth Watching: Stock Jumps 12.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 8:25AM CDT
KaloBios (KBIO) was a big mover last session, as the company saw its shares rise nearly 13% on the day. (full story)
Strength Seen in Receptos, Inc. (RCPT) as Stock Shoots up 36.78% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 7:44AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as the company saw its shares surge a whopping 37% on the day. (full story)
ARIAD Announces Webcast of Its Annual Shareholders Meeting
Business Wire - Wed Jun 11, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Annual Meeting of Stockholders will be webcast live on June 25, 2014 and can be accessed by visiting the investor relations section of the Company's website at: http://www.ariad.com/investor. (full story)
Ariad Pharmaceuticals Rises 3.02% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jun 10, 5:12PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.62 to a high of $6.88. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $6.86 on volume of 8.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 85.8% (ARIA)
Comtex SmarTrend(R) - Tue Jun 10, 10:58AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on November 22nd, 2013 at $3.67. In approximately 7 months, Ariad Pharmaceuticals has returned 85.83% as of today's recent price of $6.82. (full story)
Why Investors Are Wrong about Ariad
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jun 09, 2:51PM CDT
Ariad Pharmaceuticals has had a rough year, with the stock down over 60% on a variety of bad news for its primary drug Iclusig. More specifically, past issues with blood clots resulted in the drug being pulled from the market and then returned with... (full story)
Hyperion (HPTX) in Focus: Stock Tumbles 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 09, 7:55AM CDT
Shares of Hyperion fell about 6% on Friday while the stock is now up nearly 9% in the past one-month time frame, suggests that it requires a close watch of this firm in the near future. (full story)
Aerie Pharmaceuticals, Inc. (AERI) in Focus: Stock Rises 5.71% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 09, 7:44AM CDT
Aerie Pharmaceuticals, Inc. (AERI) was a big mover last session, as the company saw its shares rise nearly 6% on the day. (full story)
Insider Trading Alert - ENTA, REX And ARIA Traded By Insiders
at The Street - Thu Jun 05, 9:12AM CDT
Stocks with insider trader activity include ENTA, REX and ARIA (full story)
